01 Increasing Prevalence of Urinary Incontinence and Rise in Geriatric PopulationA person's quality of life and social and emotional health are significantly impacted by urinary incontinence. Urinary incontinence symptoms can be brought on by various conditions, including urinary tract infections, weakened pelvic floor muscles and urethral sphincters, menopause, pregnancy, childbirth, and post-radical prostatectomy surgery in males. According to a study by Telma Pires et al., published in the July 2020 issue of the journal Human Kinetics, stress urine incontinence affected 20.7% of female athletes worldwide. It was present in 25.9% of female athletes participating in various sports. Volleyball has a rating of 75.6%, making it the sport with the highest prevalence and influence. Female athletes had a high rate of urine incontinence, and high-impact sports may make them more susceptible to stress incontinence.Urinary incontinence is more common as people age. Several chronic illnesses and environmental variables increase the risk of urine incontinence in elderly persons. Diabetes mellitus, Parkinson's disease, dementia, stroke, prostatic cancer, chronic obstructive pulmonary disease (COPD), and arthritis are chronic conditions linked to urine incontinence. The demand for urinary incontinence treatment devices is expected to rise throughout the projected period due to an increase in the number of people suffering from urine incontinence and a high incidence of urinary incontinence globally due to the aging population.
01 Risks and Complications from the ProceduresSynthetic suburethral slings are the most used surgical methods for treating urine incontinence worldwide. Despite having excellent success rates, the procedure's difficulties prevent the industry from expanding. Some of the risks associated with suburethral sling surgery include bleeding, intestinal perforation, urethral or bladder injury, urethral or bladder mesh erosion, vaginal extrusion of mesh, urinary tract infection, pain, urinary urgency, and bladder outlet obstruction, according to a study by Cristiano Mendes Gomes et al. that was published in the International Brazilian Journal of Urology. Additionally, warnings from regulatory bodies about the potential safety risks associated with using mesh for urogynecological reconstruction significantly affected patients, surgeons, and manufacturers globally.
01 Growing Urethral Slings SegmentThe urethral slings market is predicted to grow since these are strongly indicated for surgical treatment of stress urinary incontinence. Mid-urethral sling surgery is another name for urethral sling procedures. Muscle, ligament, and tendon tissue from the woman or an animal, like a pig, may be utilized to make the sling. It could be made of synthetic materials like absorbable polymers that degrade over time or plastic that is compatible with bodily tissues.In addition to the low-risk rates and benefits of sling treatments, the segment's rise is also being aided by the rising desire for minimally invasive procedures. Boston Scientific unveiled a revision of the mesh sling system, a surgical device used to treat male patients with stress urinary incontinence. Additionally, the surgical mesh is used to stabilize the urethra neck and treat stress incontinence (SUI). The increasing prevalence of urinary incontinence and ongoing research into the treatment of urinary incontinence are the main drivers of the growth of the urethral slings market.
April 2026 Medtronic enrolled the first patient in the ENDURANCE post-approval study evaluating its Altaviva™ Tibial System for urge urinary incontinence treatment. The multicenter study is designed to evaluate long-term effectiveness and durability outcomes of the implantable tibial neuromodulation device, supporting further clinical adoption of advanced neuromodulation-based urinary incontinence therapies.
March 2026 Rohto Pharmaceutical expanded its medical device business into the Chinese market through the planned launch of a wearable neuromodulation device for managing overactive bladder symptoms. The company partnered with Australis Scientific Pty Ltd. and Beijing InnoStim Technology Co., Ltd. to introduce a non-invasive wearable solution integrated with an AI application for home-based bladder management.
January 2026 Wellspect HealthCare launched Surity™ Female External Catheter in the U.S. market, expanding its continence care portfolio with a non-invasive urinary incontinence management solution. The product was designed to support women living with severe urinary incontinence and provide an alternative approach for caregivers and patients requiring continence management solutions.
December 2025 BlueWind Medical received FDA 510(k) clearance for the Revi System, an implantable tibial electrical urinary continence device designed for patients with urgency incontinence. The system uses wireless-powered neuromodulation technology to stimulate the tibial nerve and provide a minimally invasive treatment option for urinary control disorders.